| Gene |
Antibody Ligands |
Cancer Cell Line |
| OC-3-VGH |
C-33A |
| (Observed percentages of gene expressionsa) |
| IgG |
RP215 |
108±2*b,c |
160±5 |
| |
Anti-human IgG |
105±5*c |
166±4 |
| NFκB-1 |
RP215 |
141±16 |
182±9 |
| |
Anti-human IgG |
153±10 |
176±11 |
| TLR-3 |
RP215 |
326±32 |
329±12 |
| |
Anti-human IgG |
243±25 |
141±18 |
| TLR-4 |
RP215 |
12±9 |
46±8 |
| |
Anti-human IgG |
28±18 |
71±6 |
| TLR-9 |
RP215 |
17±10 |
39±4 |
| |
Anti-human IgG |
43±8 |
60±4 |
| TLR-2 |
RP215 |
|
152±14 |
| |
Anti-human IgG |
|
116±13 |
aThe gene expressions levels of cancer cells without treatments were adjusted to
100%. (based on comparison with the internal control gene of GAPDH)
bAverage and standard deviation are presented in each case
cAll data presented are statistically significant at P<0.01 except those labeled with
*which are not statistical different from the negative control |
